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Abstract
Background: The Plasmodium falciparum dihydrofolate reductase (DHFR) and dihydropteroate
synthetase (DHPS) are enzymes of central importance in parasite metabolism. The dhfr and dhps
gene mutations are known to be associated with sulphadoxine/pyrimethamine (SP) resistance.
Objective: To investigate the effects of dhfr/dhps mutations on parasite characteristics other than
SP resistance.
Method: Parasite infections obtained from 153 Sudanese patients with uncomplicated falciparum
malaria treated with SP or SP + chloroquine, were successfully genotyped at nine codons in the
dhfr/dhps genes by PCR-ELISA.
Results & conclusion: Mutations were detected in dhfr at N51I, S108N and C59R, and in at dhps
at A/S436F, A437G, K540E and A581G, the maximum number of mutations per infection were five.
Based on number of mutant codons per infection (multiplicity of mutation, MOM), the infections
were organized into six grades: wild-types (grade 0; frequency, 0.03) and infections with MOM
grades of 1 to 5, with the following cumulative frequency; 0.97, 0.931, 0.866, 0.719, 0.121,
respectively. There was no significant association between the MOM and SP response. Importantly,
immunity, using age as a surrogate marker, contributed significantly to the clearance of parasites
with multiple dhfr/dhps mutations. However, these mutations have a survival advantage as they
were associated with increased gametocytogenesis. The above implications of dhfr/dhps mutations
were associated with MOM 2 to 5, regardless of the gene/codon locus.
Background
Falciparum malaria is still out of control, primarily
because of the ability of the parasite to develop resistance
against the used drugs. But, also the fast disseminations of
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of the parasite to develop resistance against new drugs, are
important factors [1]. Sulphadoxine/pyrimethamine (SP),
has been an alternative to CQ for treatment and control of
uncomplicated malaria in endemic countries, it was effec-
tive, affordable and complying drug. The fixed combina-
tion in SP inhibits the action of two enzymes,
dihydrofolate reductase (DHFR) and dihydropteroate
synthetase (DHPS) in folate metabolism pathway [2,3].
Mutations in the parasite genes coding for the two
enzymes, dhfr and dhps, lead to SP resistance, however, the
mutations also affect the parasite population, fitness and
evolution [4,5].
Although elimination of the asexual stages of Plasmodium
falciparum is the focus of the treatment of individual
symptomatic patients, at population level, reducing the
carriage of gametocytes is necessary to limit the transmis-
sion of malaria parasites and the spread of anti-malarial
drug resistance. In relation to SP treatment, the gameto-
cyte carriage and infectivity to mosquitoes was found to
be consistently higher in patients infected with drug resist-
ant compared with drug sensitive malaria parasites [6].
In malaria endemic areas, the host immune system acts
synergistically with chemotherapy in the clearance of par-
asites [7]. The susceptibility of parasites with mutations to
the host immune mechanisms is largely unknown. In
studies done in Mali, the term genotype-resistance index
(GRI) was introduced to correct for the differences
between the two arms of the equation; the treatment fail-
ure rate and the prevalence of parasite mutations [8]. This
index is a proxy for the role of immunity, which varies
between epidemiological settings, and in the same setting
depends on the age. The hypothesis on which this study
was based was a combination of two old observations, the
association of drug resistance with dhfr/dhps mutation,
and the implication of immunity in clearance of drug
resistant parasites. That implies, the dhfr/dhps mutant par-
asites might be more susceptible than the wild variants to
host immune clearance. Further more the study aim to
investigate the relationship between the dhfr/dhps muta-
tions and the parasite fitness in term of; in-vivo parasite
growth and gametocytogenesis. This data is complemen-
tary to a previous report in which these parameters were
analysed in relation to in-vivo drug response [9].
Methods
Study area, population and parasites
The study was carried out in Daraweesh and Kajara vil-
lages in Eastern Sudan, the details is mentioned elsewhere
[9]. The major characteristics of this setting are seasonality
and marked instability of malaria transmission, and sus-
ceptibility of people in all age groups to malaria infection.
This study was conducted in 2003, one year before the
official replacement of CQ with artesunate/SP combina-
tion therapy as first-line treatment for malaria.
All patients with uncomplicated P. falciparum malaria (n,
254) in all age groups were enrolled in the study, exclud-
ing pregnant women and severely ill patients. A modified
protocol for assessment of drug resistance was used [10].
The study design, in-vivo results and classification of treat-
ment outcome into: early treatment failure (ETF), late
treatment failure (LTF), and adequate clinical and parasi-
tological response (ACR), were presented before [9].
However, PCR was not done to confirm that all micro-
scopically confirmed ACPR infections were not having
sub-microscopic parasitaemia. Blood collected in filter
papers during 28-day follow up was used for genotyping
to confirm recrudescence.
A subset of 168 infections, obtained from patients with
(TF, 82) and randomly selected patients with (ACR, 86),
were genotyped in the P. falciparum genes dhfr and dhps.
Only 153 parasite infections were successfully genotyped
at all examined loci, 78 from patients with ACR and 75
from patients with TF (included 17 ETF, and the remain-
ing were LTF). The informed consent of the patient or
guardian was obtained, and institutional and national
ethical clearance were obtained from the Sudan Ministry
of Health.
DNA extraction, PCR and SSOP-ELISA for detection of 
drug-resistance-associated mutations
The parasite DNA was prepared from filter papers as
described before [11]. Single nucleotide polymorphisms
(SNP) and haplotypes of the SP resistance genes; dhfr and
dhps (SP), were analysed by a recently developed PCR-
SSOP-ELISA method [12]. The laboratory clones; 3D7,
7G8, Dd2, FCR3 and K1, and four field infections express-
ing the 164L of dhfr and 436/437AA, 436/437AG and
540E genotypes of dhps, respectively, were used as a stand-
ard positive control. Known SNPs of dhfr and dhps are rep-
resented in this panel of parasites. The nested PCR
followed by SSOP-ELISA were performed as described
before [12].
The multiplicity of mutations (MOM)
Based on the number of dhfr/dhps mutations regardless of
their loci (multiplicity of mutations – MOM), parasite
infections were grouped into six grades, wild infections
(MOM = 0), and infections with 1, 2, 3, 4 or 5 mutations
(MOM 1 to 5). Some parasite infections were negative for
one or more of the examined dhfr/dhps loci (n = 15) and
they were excluded from MOM grouping. The types of
mutations in the different MOM grades are shown in Fig-
ure 1. In Table 1 a cumulative MOM classification was
used to calculate the GRI and to estimate the prevalence of
mutations in relation to the treatment outcome. ParasitesPage 2 of 8
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least one dhfr/dhps mutation, by definition this includes
all parasites with any number of mutation (MOM 1–5),
and parasites of cumulative MOM 2 includes parasites
with MOM 2–5 and etc.
Statistical analysis
The Statistical Product and Service Solutions (SPSS; ver-
sion 13) software was used for the statistical analysis.
Independent T-test was used to compare between sub-
groups of patients infected by parasites with (MOM 0 to
5) but different response (ACR and TF) regarding parasite
density and patient's age. ANOVA was used for comparing
parasite densities between all study groups. The gameto-
cyte prevalence and longevity was compared between par-
asite infections with different number of mutations by
calculating the Odds Ratio and using Chi-Square Tests,
respectively.
Results
Clinical, parasitological and genotyping data
The clinical and parasitological data was presented before
[9]. Briefly, the treatment response of the two treatment
groups (SP and SP/CQ) was comparable, TF of SP alone
(31.7%) and of SP plus CQ (36.6%) was similar, and the
overall TF rate was 35.4% (90/254, PCR-corrected). The
parasite infections used in this study were obtained from
168 patients treated with SP/CQ (n = 127; mean age 22.5
± 16.4 Y) and SP alone (n = 41; 22.9 ± 15.5 Y). The prev-
alence of the individual dhfr mutations; 51I, 108N, 59R
and 164L, were 0.89, 0.89, 0.005 and 0.0, respectively,
and that of dhps; 437G, 540E, 581G, 436F and 613T, were;
0.88, 0.77, 0.13, 0.005 and 0.0 respectively.
Overall prevalence of MOM, and its relation with the 
treatment response
The subset of analysed samples (n, 153) represented most
of the SP-resistant parasite and 45% of the SP-sensitive
parasite population. Still, the MOM prevalence according
The distribution of the individual dhfr/dhps mutant codons (small bars with different shading grade) in parasites infections with diff ren  MOM (multipl city of mutations) grades (multi-bar columns) as shown umerically in y-axisFigure 1
The distribution of the individual dhfr/dhps mutant codons (small bars with different shading grade) in parasites infections with 
different MOM (multiplicity of mutations) grades (multi-bar columns) was shown numerically in y-axis. The parasite infections 
were obtained from patients with uncomplicated malaria (n = 153), genotyped at dhfr/dhps loci, and grouped into five groups 
based on the number of mutations per parasite (MOM 1 – 5), as indicated by in x-axis. The type of mutant codons were shown 
in the key.
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from the total parasite population (n, 231; the remaining
23 infections were the calculated to be negative in at least
one of the examined loci, if all 254 infections were geno-
typed) (Table 1). The overall prevalence of infections with
at least one, two, three, four or five mutations (cumulative
MOM 1–5), as estimated from the total population, were:
0.97, 0.93, 0.87, 0.72 and 0.12, respectively. The preva-
lence of cumulative MOM 0–5 was comparable between
the treatment outcome groups, the ACR and TF. Only four
parasite infections (0.026) were found carrying wild-type
alleles in all examined loci (Table 1). Alternatively, taking
all patients infected with parasites of the same MOM
grade together, the proportion of patients had TF was 25%
and 20% in groups of patients infected with parasites had
MOM 0 and 1, respectively, and 60% in patients had
infections with MOM5. The proportions of the TF in infec-
tions of MOM 2–4 ranged between the above mentioned
values (Figure 2A), however, all the differences were not
significant. The frequency of the MOM 0–5 (non-cumula-
tive) was also not different between the parasite infections
obtained from patients with ACR and TF response, and
between ETF and LTF (data not shown). The infections
with single mutation (MOM 1) were few (n = 5) and com-
parable to the wild-type infections (MOM 0) in number
(n = 4) and other characteristics as will be shown
Multiplicity of mutations, age and immunity
Patients with a TF outcome were significantly younger in
age than patients achieving an ACR (P > 0.001), but no
significant difference in age between ETF and LTF (P =
0.193). Patients infected with parasites with different
number of mutations including the wild-type parasites
(MOM 0–5), were not different in age (P = 0.839,
ANOVA) (Figure 2B, comparison between all double
bars). However, for patients infected with parasites of the
same MOM grade, patients achieved ACR were mostly sig-
nificantly older in age than patients had TF (Figure 2B,
comparison between black and white bars in each pair
separately); MOM2: (P = 0.052), MOM3: (P = 0.34),
MOM4: (0.042) and MOM5: (P = 0.019). But no signifi-
cant difference between the two groups (ACR vs TF) when
infections caused by wild parasites (P = 0.79) or parasites
with a single mutation (P = 0.76).
The role of immunity in clearance of mutant parasites was
estimated by calculation of the ratio of cumulative MOM
prevalence to the corresponding TF rate, GRI, which var-
ied between 2.03 and 2.74 (excluding MOM 5, prevalence
less than TF rate), as shown in Table 1.
Multiplicity of mutations and pre-treatment (D0) 
parasitaemia
There was no significant difference in the pretreatment
(D0) parasite density between ACR and TF donors of these
samples (P = 0.143). However, there was a certain trend of
differences in parasite density between patients infected
with parasites with different dhfr/dhps mutations (MOM 0
to 5; P = 0.066, ANOVA). For infections of the same
number of mutations (MOM), the parasite count was
higher in patients with ACR outcome if the MOM grade
was 0 or 1, and the reverse was true (i.e. higher count in
TF) if the MOM grade was 2 to 5. However, the difference
was only significant for MOM4 parasite infections, P =
0.022, Independent T-Test, (Figure 2C).
Multiplicity of mutations and gametocytogenesis
Gametogenesis, was defined as the ability of the infections
to produce gametocytes at least once during follow up
(D0, 3, 7, 14, 21 and 28), while gametocyte longevity,
refers to the number of times gametocytes were detected
during the follow up. The later was scaled from 0 (no
gametocyte detected) to 6 (gametocytes detected in the 6
days of follow up). Both parameters are indices for game-
tocytogenesis in-vivo. None of the wild-type or MOM1
infections (n = 9) produced gametocytes during the fol-
low up, while parasites with multiple mutations (MOM
2–5) had high rates of gametogenesis (60 – 70%), the dif-
Table 1: The frequency of the different dhfr/dhps multiple mutations (multiplicity of mutations, MOM), in parasite infections obtained 
from patients with different treatment outcome, ACR and TF, following SP and CQ therapy, and the overall prevalence rate of MOM 
and the corresponding mutation/TF ratio.
Multiplicity of mutation (MOM) Frequency of cumulative MOM Overall prevalence of cumulative MOM Mutation/TF ratio (GRI)
ACR (n,78) TF (n,75) P-value Chi-Square measured N1 = 153 calculated N2 = 231
Null (wild) 0.038 (3) 0.013 (1) 0.640 2.6% (4) 03% (7)
Single 0.962 (75) 0.987 (74) 0.640 97.4% (149) 97.0% (224) 2.74
Double 0.910 (71) 0.973 (73) 0.189 94.1% (144) 93.1% (215) 2.63
Triple 0.846 (66) 0.907 (68) 0.374 87.6% (134) 86.6% (200) 2.45
Quadruple 0.679 (53) 0.800 (60) 0.131 73.9% (113) 71.9% (166) 2.03
Quintuple 0.103 (8) 0.160 (12) 0.416 13.1% (20) 12.1% (28) <1
ACR, adequate clinical response; TF, treatment failure; MOM, multiplicity of mutations; Mutation/TF ratio = prevalence of MOM (calculated)/TF 
rate (35.4)]. N1, number of genotyped samples; N2, total number of samples; GRI, genotype-resistance indexPage 4 of 8
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Comparisons between parasite groups of different dhfr/dhps genotype profile; wild parasite infections and infections with differ-ent number of mutations (MOM 1 to MOM 5), a d in each parasi e group b t een infec ions obtained from patients attend d adeq te clinical resp e (ACR) (white bars  a d t ose ad treatm nt failure (TF) (b k bars)Figure 2
Comparisons between parasite groups of different dhfr/dhps genotype profile; wild parasite infections and infections with differ-
ent number of mutations (MOM 1 to MOM 5), and in each parasite group between infections obtained from patients attended 
adequate clinical response (ACR) (white bars) and those had treatment failure (TF) (back bars). The test parameters were; A. 
The proportions of patients with different treatment outcome in each group (upper) B. The mean ages of the parasite donors 
in years (middle). C. The pre-treatment parasite density (lower). The pattern in wild infections and infections with single muta-
tion (MOM 1) was different from that in infections with MOM 2 to 5.
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Tests). The odd ratios confirmed the difference in game-
togenesis between MOM 0 – 1 and MOM 2 – 5 parasite
infections (Table 2). For the comparison of the gameto-
cyte longevity in infections with parasites of different
MOM grades, there was significant difference between
infections with MOM 0 – 1 and MOM 2 – 5, (P = 0.002),
Table 2.
Discussion
The mutations of genes encoding important enzymes
such as DHFR and DHPS, should affects parasite metabo-
lism and indeed change certain parasite characteristics.
The goal of this study is to understand the implications of
gene mutations of the two enzymes in certain parasite
characteristics, namely the susceptibility of the parasite to
immune clearance (parasite fitness), sexual reproduction
(gametocytogenesis) and asexual reproduction (parasite
growth).
The dhfr/dhps gene mutations are known to be involved in
parasite resistance to SP [2,3], and in-vivo studies have
shown that immunity is involved in clearance of drug
resistant parasites [9,13]. Taken together, the dhfr/dhps
mutations are probably involved in immune clearance of
SP resistant infections. In this study the ratio of TF to prev-
alence of the predominant quadruple dhfr/dhps mutations
(MOM 4) was approximately 1: 2, that was a circumstan-
tial evidence for the role of host immunity in clearance of
mutant parasites. The supporting evidence was the higher
age (a surrogate marker for immunity) of the successfully
treated patients. Interestingly, the ratio of MOMs preva-
lence to the actual treatment failure (2.03 and 2.74) is
similar to the GRI (genotype resistance index) in Mali (1.6
to 2.8), a region epidemiologically similar to this study
site [14], although different drugs were used. The specific
evidence for the increased suscebtibilty of the dhfr/dhps
multi-mutant parasites to immune clearance was the dif-
ference in age of the patients infected with parasites with
the same number of mutations (MOM grade) but had dif-
ferent treatment outcome. This difference in age (ACR vs
TF) was limited to the parasite infections with multiple
mutations (MOM 2–5), but not to infections with wild
parasites and parasites with single mutation (Figure 2B).
For identification of the most important mutations (loci),
larger sample size is needed, however, in this study, 51I,
108N, 437G and 540E were the predominant mutations
(Figure 1). Furthermore, the reduced resistance of multi-
mutant parasites to host immunity is a sign of reduced fit-
ness, supporting previous reports [4,5,15]. The degree of
immunity which is required for clearance of parasite with
specific number of mutation was estimated by the GRI
value. The interpretation of this data indicates that, there
are at least three factors directly contributing to parasite
clearance (ACR): the drug (SP), immunity (represented by
age) and parasite mutations (MOM > 1). The paradox is
that, the dhfr/dhps mutations provide the parasite the abil-
ity to resist chemotherapy, while it renders it more suscep-
tible to the host immunity.
The pre-treatment parasite density probably reflects the in-
vivo parasite growth, assuming that sequestration is con-
fined to severe malaria infection; and the peripheral para-
sitaemia represents the total parasite load. In this study,
the parasite growth was influenced by dhfr/dhps mutations
where growth of wild and parasites with single mutation
(MOM 1) was relatively higher from that of multi-mutant
parasites in patients achieved ACR and the reverse was
true in case of TF (Figure 2C). However, these results
(trends) need to be taken with precaution because the
sample size was small and the accuracy of the microscopic
estimation of parasitaemia is not high, in addition para-
site sequestration is not confined to severe malaria. In a
previous study in the same site it was found that, there was
significant association between reduced parasite growth
and dhfr/dhps mutations [15].
Table 2: The gametocyte rate – gametogenesis – and gametocyte longevity (gametocytogenesis) in malaria infections caused by wild-
type parasites and parasites with different number of dhfr/dhps mutations (MOM 1 – 5). The differences in gametogenesis between 
parasites with different MOM were estimated by calculation of the Odd ratios with reference to MOM5.
Gametocytogenesis
Gametogenesis Gametocyte longevity
Yes No Odd Ratio 95% CI
Lower Upper 0 1 2 3 4 5 6 (max)
*Wild (4) 0 1.0 3.330 1.707 6.511 1.0 0 0 0 0 0 0
*Single (5) 0 1.0 3.330 1.707 6.511 1.0 0 0 0 0 0 0
Double (10) 0.60 0.40 1.556 0.319 7.597. 0.40 0.20 0.30 0.10 0 0 0
Triple (21) 0.62 0.38 1.436 0.391 5.269 0.38 0.33 0.19 0.05 0 0.05 0
Quadruple (93) 0.69 0.31 1.057 0.364 3.028 0.31 0.24 0.23 0.17 0.05 0 0
Quintuple (20) 0.70 0.30 1.000 0 0 0.30 0.20 0.30 0.15 0.05 0 0
* In the two groups the test parameters were significantly lower than in the other groupsPage 6 of 8
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increases with treatment failure [16], treatment with SP
[17] and younger age [9]. In this study, the gametogenesis
was significantly higher in parasites with multiple dhfr/
dhps mutations compared to wild type and parasites with
single mutation, as recognized in other studies [18,19].
However, only two dhfr/dhps mutations (MOM2) were
needed to enhance the gametocytogenesis significantly,
with no additive effect for more mutations (MOM 3–5).
In the in-vivo study, the patient achieved ACR had signifi-
cantly lower frequency of gametocytaemia compared to
patients who had TF. The association between gametocy-
togenesis and dhfr/dhps mutations was independent of the
treatment outcome and the host age. That is because, there
was no association between the treatment outcome and
the mutations in this study, and the age of patients
infected with wild-type parasite and parasites with MOM1
(median 13 years) was not different from the age of
patients who had TF (median, 12 years). Also, the differ-
ences cannot be due to gametocytogenic effect of SP treat-
ment, as all patients were treated with SP. Although, the
gametocytogenesis is the corner stone in the spread of the
resistant strains, there are only few studies that had
evoked the issue at the molecular level [15,19]. Finally, it
is difficult to look at these parasite characteristics of game-
tocytogenesis, immune clearance and in-vivo parasite
growth in isolation of drug resistance since they are not
independent from each other, thus, further studies are
needed for detailed molecular exploration.
In conclusion, the dhfr/dhps gene mutations in P. falci-
parum are probably affecting the parasite fitness by render-
ing the parasite more susceptible to immune clearance
than the wild-type variants. The increased immune clear-
ance of mutant parasites can explain the lack of associa-
tion between the prevalence of dhfr/dhps mutations and
the TF rate in this setting. Furthermore, there were indica-
tions that the in-vivo asexual growth of the dhfr/dhps multi-
mutant parasites was lower compared to wild types, while
the gametocytogenesis in the former group was signifi-
cantly higher than in the later. That is more likely an evo-
lutionary mechanism compensating for the reduced
asexual reproduction, and also can explain the fast propa-
gation of SP resistance. Finally, the above-mentioned
implications need only two (double) mutations in the
dhfr/dhps genes irrespective of their codon/gene locus,
while it was reported, SP resistance is associated with
higher number of mutations in specific loci.
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